My response to the unsettled hand architecture — tendon vs linkage vs direct-drive, DOF count, motor placement — is to hedge with a range: A17, B06, B20, not bet one design. Independent analysis gives this layer the lowest certainty of technology choice in its peer set; that route-risk defines it. Hedging is rational but doesn't remove the risk: a winning design I don't hold could strand part of the range. The same analysis frames me as a cross-over entrant on cost-performance, not a premium leader, with the coreless-motor half of the actuator commoditizing, low moat.
We build the hand, and then we build the parts inside the hand - the micro-motor, the micro-gearbox, the lead screw, the control electronics. That is the '1+1+1' platform, and the value we defend is the drive system in the palm, not the shell around it. The core business is real and shipping: about 1.72 billion yuan of revenue in 2025, micro-transmission and precision parts sold into cars, medical devices, and industry, net cash with no long-term debt. The dexterous-hand frontier is genuine - we ship A17, B06, and B20 hands and run a dedicated subsidiary for them - but I won't size it for you, because it is not yet a broken-out revenue line. And I won't smooth the recent quarter: after a strong, accelerating 2025, the first quarter of 2026 reversed, net profit down 25%. Whether that is a blip or a slowdown is the question I watch.
I make the integrated dexterous hand plus the parts inside it: micro-motors — including a 4mm brushless coreless motor in mass production — micro-gearboxes, reducers, lead screws, and motor-control electronics. This is the '1+1+1' platform: micro-transmission, micro-motor, and motor-control systems, backed by a 4-42mm full-stack self-developed motor series. Independent analysis names me a cross-over entrant supplying integrated dexterous-hand drive modules on cost-performance positioning from that precision micro-transmission base. The value I defend sits in the drive system in the palm.
We ship A17 (17 active DOF, finger-joint drive units), B06 (6 DOF, linkage transmission, heavy-duty), and B20 (20 DOF, 600g, ≥30N grip, 5-12N fingertip, CES Jan 2026) — real hardware, not renders. The ZWHAND platform and a 50M yuan subsidiary back them. But revenue stays micro-transmission (~60%), precision parts (~35%), molds (~5%); humanoid sales are embedded, not broken out. Mass production still ramping. A product-backed option on the dexterous-hand layer, not yet a sized business.
My net assets to shareholders stand at about 3,483 million yuan, up 7.96%, against total assets of about 4,318 million yuan — equity ratio near 81%, net cash, no long-term debt, clean unqualified audit. Weighted ROE 7.14%, depressed not by unprofitability but over-capitalization — about 3.48 billion equity and 4.32 billion assets against only about 1.72 billion revenue, with much of the 2021 IPO's roughly 2.0 billion yuan in low-return wealth-management. The flip side: a self-funded war chest to bankroll the robotics build-out without raising external capital, an option cheap to hold.
Through 2025 we built quarter on quarter: revenue 1,715.5M yuan (+12.5%), net profit 254.3M yuan (+13.0%), operating cash flow +28.9%. Quarterly profit accelerated — 54.7, 58.6, 68.0, 73.1M yuan. Then Q1 2026 reversed hard: revenue 357.5M yuan (-2.7%), net profit 41.0M yuan (-25.2%), below every 2025 quarter, ROE 1.17%. Whether margin blip or auto-consumer slowdown, we watch H1 2026 for volume and margin recovery.